Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Some US coverage on Seeking Alpha

<< Previous

Bullboard Posts

Next >>

Post by stocksarefunon Dec 16, 2020 10:30am

140 Views

Post# 32118104

Some US coverage on Seeking Alpha

The Marketing needs to continue. Somewhat pathetic that we have less than 29k shares traded on both the TSX.V and OTC exchanges at this point today after our Prime Minister announced on Live television that we'd be receiving 6.7M dollars in grant money, and that our research and science was evaluated by the highest officials at Health Canada.

https://seekingalpha.com/news/3644580-arch-biopartners-nabs-govt-grant-for-development-of-covidminus-19-peptide-therapy

Let's get this going!!!

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading